ImmunityBio Inc is a biotechnology company focused on developing innovative immunotherapy treatments to harness the body's immune system in the fight against cancer and infectious diseases. The company specializes in the discovery and commercialization of novel therapies that aim to stimulate an immune response, with a particular emphasis on enhancing the effectiveness of existing cancer treatments. By leveraging cutting-edge research and technology, ImmunityBio is dedicated to improving patient outcomes and finding breakthrough solutions for complex medical challenges. Read More
The Saudi Food and Drug Authority encouraged the company to submit a regulatory filing for its recombinant Bacillus Calmette-Guérin, which the company expects to submit within weeks.
ImmunityBio, Inc. (NYSE: IBRX), a commercial stage immunotherapy company developing next generation therapies that drive immunological memory and restore immune competence, today announced that the Company held productive regulatory discussions with the Saudi Food and Drug Authority (SFDA) in Riyadh, convened under the Saudi-USA Biotech Alliance hosted by the Ministry of Investment of Saudi Arabia (MISA). The engagement advanced two regulatory priorities: (1) SFDA encouraged the Company to submit a regulatory package for its recombinant BCG (rBCG) to expand BCG access in Saudi Arabia and address the ongoing global BCG shortage, and (2) ImmunityBio and SFDA initiated discussions regarding the expansion of ANKTIVA® (nogapendekin alfa inbakicept) in combination with checkpoint inhibitors (CPIs) to additional tumor types in the CPI relapsed population.
Retail investors are now looking forward to a full approval of Anktiva in the EU for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ.
ImmunityBio (NASDAQ: IBRX) is rapidly transforming into a commercial powerhouse, fueled by the explosive growth of its lead immunotherapy, ANKTIVA. Following a year of breakthrough regulatory wins and clinical milestones, the company has reported a staggering 700% year-over-year increase in preliminary net product revenue, reaching approximately $113 million for 2025.
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the launch of ResQ215B, a Phase 2 clinical study evaluating a novel chemotherapy-free and lymphodepletion-free combination immunotherapy in patients with indolent B-cell non-Hodgkin lymphoma (iNHL), including Waldenström’s Macroglobulinemia.
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Small-cap stocks trading near the $5 level are back on investor watchlists as volatility and headline-driven momentum return to the market. ENDRA Life Sciences (NASDAQ: NDRA), ImmunityBio (NASDAQ: IBRX), Movano Inc. (NASDAQ: MOVE), and Rivalry Corp. (TSXV: RVLY) are all seeing renewed interest, driven by a mix of clinical progress, revenue developments, compliance milestones, and sector-specific trends.
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company developing cytokine and cellular immunotherapies designed to restore immune competence, today announced updated Phase 2 clinical results from QUILT 3.078 (NCT06061809), evaluating a chemotherapy-free combination immunotherapy regimen in patients with second-line recurrent or progressive glioblastoma (GBM), as well as patients treated under single-patient INDs (spINDs) across first- to third-line disease.
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B End-of-Phase meeting with the U.S. FDA regarding the Company’s supplemental Biologics License Application (sBLA) for ANKTIVA® (nogapendekin alfa inbakicept) plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary tumors.
